

July 10, 2018

Introducing Nuwiq® 3000, 4000 IU vials for dosing flexibility and personalizing Hemophilia A treatment

Dear Healthcare Professional,

Octapharma Canada is pleased to announce the introduction of 3000 and 4000 IU vial sizes for Nuwiq®, the 4th generation rFVIII indicated for the treatment and prophylaxis of bleeding in patients of all ages with hemophilia A (congenital FVIII deficiency).¹ Nuwiq® is also indicated for the peri-operative treatment of hemophilia A patients.¹

With the addition of these vials, the range of available strengths now include 250, 500, 1000, 2000, 3000 and 4000 IU. Each vial of Nuwiq® is provided with a pre-filled syringe containing 2.5 mL of diluent for reconstitution. The uniform diluent volume of 2.5ml for all vial sizes makes Nuwiq the only rFVIII with the lowest diluent volume across the entire range.

The larger vial strengths were added to provide more options for dosing and to aid clinicians in employing a personalized approach to treating hemophilia A patients, including pharmacokinetic (PK)-guided prophylaxis. The expanded range offers physicians and healthcare professionals greater treatment flexibility and selection of combination of vials that minimises product wastage.

The new 3000 and 4000 IU vials are now available. Blood banks and Health Care Professionals should contact their local CBS site to ascertain exact product availability dates at their location.

For complete prescribing information, please consult the Nuwiq® Product Monograph at <http://www.octapharma.ca/en/about/products-therapies/products-in-canada.html>. For additional information please contact medical information at: medinfo@octapharma.ca or call 1-888-438-0488.

Sincerely,



Lidia Cosentino, Ph.D.
Director, Medical and Scientific Affairs